Alimetry has raised an oversubscribed US $18m A2 financing round to commercialize its wearable gut health monitoring device, capitalizing on increased adoption by a growing cohort of US hospitals.
Advances in ALL at ASH Meeting Include New Blinatumomab Data and More
In the phase III ECOG-ACRIN E1910 study presented at the American Society of Hematology (ASH) annual meeting, consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival